News

SAB Biotherapeutics’ DiversitAb platform has generated specialized antibodies against multiple regions of an abnormal self-reactive antibody, or autoantibody, associated with neuromyelitis optica spectrum disorder (NMOSD). The new antibody-based therapy was found to effectively bind to the NMOSD-causing autoantibody and neutralize it in both in vitro (in lab dishes) and in vivo (inside a…

The CAR T-cell therapy CT103A appears safe generally and may ease disability and improve the quality of life in adults with relapsed or refractory neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4), according to data from a small Phase 1 clinical trial. “In this…

The onset of neuromyelitis optica spectrum disorder (NMOSD) at an older age is linked with a greater likelihood of spinal cord involvement at the first disease attack, fewer relapses, and greater disability, according to a study in China. “Age of disease onset correlates with clinical characteristics and prognostic outcomes…

The Brazilian Health Regulatory Agency has approved Uplizna (inebilizumab-cdon) for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4-IgG). The Horizon Therapeutics’ therapy is the first and only man-made antibody against CD19 — a cell surface protein present…

The activation of two types of immune cells — called natural killer (NK) and natural killer T-cells (NKT) — may contribute to the abnormal immune attacks that drive neuromyelitis optica spectrum disorder (NMOSD), a study suggested. The profile of these cells in NMOSD patients differed notably from that observed…

Pillartree Limited, a new subsidiary of Amgen, has struck a deal to acquire Horizon Therapeutics, which markets Uplizna (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD). Last month, Horizon announced that it was in preliminary discussions about a potential sale to three pharmaceutical companies — Amgen,…

People with neuromyelitis optica spectrum disorder (NMOSD) who are diagnosed with at least one non-immune system comorbidity, or simultaneous disease, are at a higher risk of vision loss and paralysis than those without such conditions, a study found. NMOSD patients with these comorbidities also were significantly more likely to…

People with neuromyelitis optica spectrum disorder (NMOSD) and related neurological conditions show reduced brain volume compared with individuals without such diseases, a new study highlights. The results indicate that rates of volume loss in the thalamus — a brain region that helps to relay motor and sensory signals —…

Being positive for or showing high levels of antibodies against the aquaporin-4 (AQP4) protein at diagnosis doesn’t predict worse outcomes for people with neuromyelitis optica spectrum disorder (NMOSD), according to a small study. Plasma exchange therapy was linked with a trend for slower disability progression, although it wasn’t…

People with neuromyelitis optica spectrum disorder (NMOSD) have increased levels in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — of three inflammatory biomarkers, a new study shows. The elevated concentrations of these biomarkers — YKL-40, sCD163, and sCD14 — also…